Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (27)	2/9/1999 10:11:00 PM
From: scaram(o)uche	Respond to of 438

SM: Yes, well, the call was pure dumb luck. Cheers! Rick

To: StockMiser who wrote (27)	2/10/1999
From: Henry Niman	Respond to of 438

Several ENMD/BMY stories are linked to the Anti-Angiogenesis table in the New Therapeutics section of biocognizance.com

To: StockMiser who wrote (27)	2/10/1999 12:35:00 AM
From: jeffbas	Read Replies (1) \| Respond to of 438

I am not happy to read the ENMD/BMY announcement at all! The Boston Globe today quoted the president of GZMO as saying their compound is essentially the "next generation" of the earlier Folkman research (that ENMD got). I would say the probabilities of the GZMO product being good are lower if the first generation products (of ENMD) are no good. Wouldn't you? I do not think Bristol Myers was ambiguous. Logically, GZMO should sell off as well, in my opinion, until the original research on their new compound is published. I would have been much happier if GZMO CEO had called their product a new class of products and not next generation. It looks as if my earlier prediction that the stock could pull back to $3 may be realized soon.